Granules India Announces Closing of Acquisition of Senn Chemicals, Strengthening Capabilities in Peptide Therapeutics and CDMO Services
Mumbai,India–April10,2025:GranulesIndiaLimited(BSE:532482,NSE:GRANULES) today announced the successful closing of the acquisition of Senn ChemicalsAG, a Swiss- basedContractDevelopmentandManufacturingOrganization(CDMO)specializinginpeptide developmentandmanufacturing.ThismarksastrategicmilestoneinGranules’transformation into a science- and innovation-led organization and extends its capabilities into the fast- growing peptide therapeutics segment.
TheacquisitionfollowsthesigningofadefinitivesharepurchaseagreementinFebruary2025, underwhichGranules,throughitswhollyownedIndiansubsidiary,GranulesPeptidesPrivate Limited, acquired 100% of the equity of Senn Chemicals from the founding Senn family. Founded over 60 years ago, Senn Chemicals has built a strong reputation as a specialist in Liquid-Phase Peptide Synthesis (LPPS) and Solid-Phase Peptide Synthesis (SPPS), servinginnovatorsandbrandownersacrosspharmaceutical,cosmetic,aminoacidderivative (AAD), and theragnostic markets.
The Senn Chemicals brand and its operations in Dielsdorf, Switzerland, will operate under Granules’ ownership, with a commitment to maintaining the company’s scientific excellence and customer focus.
Dr. Krishna Prasad Chigurupati, Chairman & Managing Director, Granules India, said, "The acquisition of Senn ChemicalsAG marks a pivotal step in Granules’strategic evolution into a science- and innovation-led organization. By entering the rapidly growing peptide therapeutics segment and building on Senn’s specialized CDMO capabilities, we are well- positionedtodeliverhigh-quality,next-generationtreatments.Senn’sspecializedexpertisein peptide development and its strong customer relationships complement Granules’ manufacturingstrength and global reach. Together, we aim to drivemeaningful impact in the complex therapeutics space."
The acquisitionwillenable Granulesto acceleratedevelopment andmanufacturingof GLP-1 receptor agonists and other peptide-basedAPIs, addressing the growing demand in anti- diabetic, anti-obesity, and other next-generation therapeutic areas. Granules and Senn have alreadyinitiatedjointdevelopmentactivitiesinthisspace,withabroaderpeptideAPI pipeline planned.
ThistransactionalsomarksGranules’forayintotheCDMOspace,withSenn’sestablished CDMO business providing a strong platform for growth. The acquisition enhances Granules’ global footprint and provides access to a regulated market client base and highly skilled scientific talent in Europe.
Advisors
Stifel Nicolaus India served as the exclusive financial advisor to Granules India on the transaction. Loyens&Loeff acted as legal advisor, Deloitte as financial and tax advisor, providing financial and tax due diligence services and Kroll provided valuation advisory services for the transaction.
AboutSenn Chemicals
SennChemicals,foundedin1963andheadquarteredinDielsdorf,Switzerland,isaspecialist in custom peptide manufacturing, supporting global clients across Pharmaceuticals, Cosmetics and Theragnostic industries, from early development to commercial production. WithexpertiseinLiquid-PhasePeptideSynthesis(LPPS)andSolid-PhasePeptideSynthesis (SPPS), Senn offers development and manufacturing solutions for peptides, peptide fragments, and amino acid derivative (AAD). The company’s state-of-the-art capabilities includeanalyticalmethoddevelopment,automatedpeptidesynthesis,andscale-upexpertise. Its GMP and non-GMP manufacturing capabilities cover NCEs for clinical trials, kilo-scale production of cosmetic peptides, andAADs at commercial scale.
AboutGranulesIndiaLtd.(BSE:532482,NSE:GRANULES)
Granules India Limited, incorporated in 1991 is a vertically integrated fast growing Indian pharmaceutical company headquartered at Hyderabad with best-in-class facilities and commitmenttooperationalexcellence,quality,andcustomerservice.Granulesisamongthe fewpharmaceuticalcompaniesintheworldtobepresentinthemanufacturingofentirevalue chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs). Granules products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extendingtoover80+countrieswith officesacross India andtheUSA.The Companyhas10 manufacturing facilities out of which 8 are in India and 2 in the USA and has regulatory approvalsfromUSFDA,EDQM,EUGMP,COFEPRIS,WHOGMP,TGA,KFDA,DEA,MCC,
andHALAL.
MediaContact: PriyankaChawla Manager-CorporateCommunications priyanka.chawla@granulesindia.com |
InvestorsContact: ChaitanyaTummala Company Secretary investorrelations@granulesindia.com |
✍ Share Your Knowledge with Our Community!
get rewards for paying bills
upto ₹250 off when you pay your first bill on CRED